VYNE Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for VYNE Therapeutics Inc. (VYNE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-39.83-28.45-23.21-73.33-255.57
Depreciation & Amortization0.00-0.260.070.100.30
Stock Based Compensation3.303.314.308.0818.10
Change in Working Capital5.000.062.28-1.72-40.33
Change in Accounts Receivable-0.900.4111.217.71-17.14
Change in Inventory0.000.000.100.11-6.05
Change in Accounts Payable6.01-0.56-8.68-2.68-12.98
Change in Other Working Capital-0.110.21-0.352.47-4.17
Other Operating Activities0.000.004.2317.14158.48
Net Cash from Operating Activities-33.97-25.34-29.20-56.37-137.08
Investing Activities
Capital Expenditures-0.120.000.000.000.11
Acquisitions0.005.0015.670.0038.64
Purchases of Investments23.48-62.350.001.0350.58
Sales/Maturities of Investments84.00-62.350.001.0350.58
Other Investing Activities0.005.0015.670.000.00
Net Cash from Investing Activities23.37-57.3515.671.0389.11
Financing Activities
Debt Repayment0.000.000.00-36.430.00
Common Stock Issued0.0082.821.4775.9861.64
Common Stock Repurchased-0.14-0.36-0.03-0.29-0.14
Other Financing Activities-0.140.000.00-0.29-0.14
Net Cash from Financing Activities-0.1482.391.6539.7861.81
Summary
Net Change in Cash-10.75-0.30-11.88-15.5613.83
Cash at Beginning of Period30.6730.9842.8658.4244.58
Cash at End of Period19.9330.6730.9842.8658.42
Free Cash Flow-34.09-25.34-29.20-56.37-137.20
Supplemental Disclosures
Interest Paid0.000.000.002.393.94